** Shares of Immunome Inc IMNM.O down 10.2% to $8.40 post-market as biotech firm looks to raise equity
** Bothell, Washington-based oncology specialist commences $125 mln stock offering
** Co intends to use net proceeds to fund clinical and preclinical development of pipeline assets, and general purposes, per the SEC filing
** JP Morgan, TD Cowen, Leerink and Guggenheim are jt bookrunners
** With ~62.4 mln shares outstanding, IMNM has ~$583 mln market cap, per LSEG data
** Shares closed up 1.2% at $9.35 on Weds. Still, stock has lost 12% YTD and about 50% over the past 12 months
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.